Evidence map›Paper›PMID 42664975›Full record

ArticleCell systems2026

PROFET predicts continuous gene expression dynamics from scRNA-seq data to elucidate heterogeneity of cancer treatment responses.

Yu-Chen Cheng, Hyemin Gu, Thomas O McDonald, Wenbo Wu, Shubham Tripathi, Cristina Guarducci, Douglas Russo, Daniel L Abravanel, Madeline Bailey, Yue Wang and 6 more

Abstract read
In one paragraph

Article in Cell systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Antibody-drug conjugate engineering: from design to efficacy and safety.Signal transduction and targeted therapy · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Yu-Chen ChengDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Hyemin GuDepartment of Mathematics and Statistics, University of Massachusetts Amherst, Amherst, MA, USA.
Thomas O McDonaldDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Wenbo WuHarvard-MIT Health Sciences and Technology, Cambridge, MA, USA.
Shubham TripathiYale Center for Systems and Engineering Immunology and Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Cristina GuarducciDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Douglas RussoDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Daniel L AbravanelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA.
Madeline BaileyDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
Yue WangIrving Institute for Cancer Dynamics and Department of Statistics, Columbia University, New York, NY, USA.
Yun ZhangState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yannis PantazisInstitute of Applied and Computational Mathematics, Foundation for Research and Technology-Hellas, Heraklion, Greece.
Herbert LevineCenter for Theoretical Biological Physics, Northeastern University, Boston, MA, USA; Department of Physics, Northeastern University, Boston, MA, USA.
Rinath JeselsohnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Markos A KatsoulakisDepartment of Mathematics and Statistics, University of Massachusetts Amherst, Amherst, MA, USA. Electronic address: markos@umass.edu.
Franziska MichorDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA; The Broad Institute of MIT and Harvard, Cambridge, MA, USA; The Ludwig Center at Harvard, Boston, MA, USA. Electronic address: michor@jimmy.harvard.edu.

Funding

Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI LEIF W ELLISEN, NANCY U LIN · 2013 to 2026
$30.1M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Quantitative systems biology of glioblastoma cells and their interactions with the neuronal and immunological milieuU54CA283114 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Forest M White · 2023 to 2026
$9.7M
Shared Resource Core 2: Clinical Artificial Intelligence CoreU54CA274516 · NCI · DANA-FARBER CANCER INST · PI Ross I. Berbeco · 2023 to 2026
$8.1M
NCI NIH HHS P50 CA168504NCI NIH HHS U54 CA274516NCI NIH HHS U54 CA283114NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Single-cell RNA sequencing (scRNA-seq) profiles cellular heterogeneity but captures only static snapshots, limiting inference of gene expression dynamics. We developed PROFET (particle-based reconstruction of generative force-matched expression trajectories), a framework that reconstructs continuous, nonlinear single-cell trajectories from sparsely sampled scRNA-seq time series. PROFET combines a particle-based gradient-flow algorithm with simulation-free force matching to accurately infer cellular dynamics. Across mouse and human in vitro datasets and an in vivo axolotl regeneration dataset, PROFET achieved 2.6-12.5× lower prediction error than ten state-of-the-art trajectory inference methods. Applying PROFET to newly generated scRNA-seq data from a palbociclib-treated MCF7 cell line and three published breast cancer patient datasets, we reconstructed treatment-response trajectories and identified a resistant cell subpopulation exhibiting large phenotypic shifts and enrichment of the surface markers UNC5B, TLR3, PCDH19, PROCR, SLITRK6, and SEMA6B. PROFET provides a biologically grounded framework for reconstructing cell-state dynamics from static single-cell data across development, regeneration, and therapeutic response. A record of this paper's transparent peer review process is included in the supplemental information.

Indexed as

breast cancer resistanceCDK4/6 inhibitor responsecell-state transitionsforce matchinggene expression dynamicsgradient-flow modelingphenotypic heterogeneitysingle-cell RNA sequencingtrajectory inference

Identifiers

PMID42664975
PMCPMC13528695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.